Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human CCN1
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal
01
Overview
Recombinant human CCN1 (also known as cysteine-rich angiogenic inducer 61 or CYR61) is a research-grade recombinant protein. It is a secreted, matrix-associated matricellular protein that belongs to the CCN family. CCN1 plays a critical role in cell adhesion, migration, proliferation, chemotaxis, and angiogenesis by binding to various integrins (such as alpha-v/beta-3, alpha-v/beta-5, and alpha-6/beta-1), syndecan-4, and heparan sulfate proteoglycans. While it has been investigated in preclinical animal models for conditions such as focal segmental glomerulosclerosis (FSGS), bone repair, and microglial depletion, it is not currently developed as a clinical-stage therapeutic asset by any pharmaceutical company. It is primarily manufactured and sold as a research-use-only (RUO) reagent by life science suppliers including R&D Systems, Cusabio, PeproTech, and Abcam.
- Other names
- recombinant human CCN1recombinant human CYR61recombinant human cysteine-rich angiogenic inducer 61recombinant human GIG1recombinant human IGFBP10
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))α6β1 (Integrin alpha-6/beta-1 complex)αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)SDC4 (Syndecan-4)
Beyond the preview
Go deeper on recombinant human CCN1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human CCN1.